ArticleStructural heart : the journal of the Heart Team2025
Atrioventricular Block After EVOQUE Transcatheter Tricuspid Valve Replacement.
Article in Structural heart : the journal of the Heart Team, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Conduction System Disease: Fascicles to Complete Block.JACC. Case reports · 2026Article
- Editorial: pacing after transcatheter tricuspid valve replacement: where are we going, where do we stand?European heart journal. Case reports · 2026Article
- Paroxysmal atrioventricular block: A warning sign for permanent block after transcatheter tricuspid valve replacement.HeartRhythm case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
•Based on a real-world study of 106 Evoque transcatheter tricuspid valve replacement (TTVR) recipients, a total of 14 (25%) cases of new atrioventricular (AV) block occurred after Evoque implantation in the 55 patients without prior pacemakers who met study inclusion criteria. This incidence is similar to that reported in the TRISCEND II clinical trial.•New AV block occurred in a median of 26 hours after Evoque TTVR (interquartile range: 5-60 hours), but there were cases of new AV block that occurred as late as 7 days after the procedure.•Of the 14 new cases of AV block, 12 were treated successfully with implantation of a leadless pacemaker (Micra) under fluoroscopic guidance without procedural complications or compromising the valve implantation.•The institutional strategy of 48-hour post-Evoque inpatient monitoring for all patients followed by mobile cardiac outpatient telemetry identified 11 of 14 cases of new AV block as before discharge from the hospital and 1 case as an outpatient before symptom onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.